IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

The addition of anagliptin to insulin and metformin therapy may improve glycemic control in patients with type 2 diabetes while maintaining an acceptable safety profile.

Pregnant women with type 1 diabetes who used hybrid closed-loop insulin delivery with Control-IQ technology spent more time ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) ...

A study finds that inhaled insulin is as effective as traditional injections for children with type 1 diabetes during ...

During a clinical trial, around 83% (10 out of 12) of patients who received a full dose of Zimislecel achieved complete ...

Once-weekly efsitora vs once-daily degludec was associated with comparable glycemic control outcomes and improved ...

A new stem cell-based treatment helped most trial participants with severe type 1 diabetes stop insulin use, offering hope ...

A clinical trial has shown that Ozempic improves blood glucose levels and weight loss in overweight type 1 diabetics who use ...

Researchers at a recent American Diabetes Association meeting reported that efsitora, experimental once-weekly insulin, was comparable to daily insulins in nearly a thousand adults with type 2 ...

Researchers found a higher daily intake of red meats, dairy low fat, pizza and other savoury snacks were the main culprits.